Alnylam Pharmaceuticals Inc (ALNY.OQ)
ALNY.OQ on NASDAQ Stock Exchange Global Select Market
74.38USD
7 Dec 2018
74.38USD
7 Dec 2018
Change (% chg)
$-5.35 (-6.71%)
$-5.35 (-6.71%)
Prev Close
$79.73
$79.73
Open
$80.00
$80.00
Day's High
$81.09
$81.09
Day's Low
$74.05
$74.05
Volume
342,985
342,985
Avg. Vol
330,423
330,423
52-wk High
$153.80
$153.80
52-wk Low
$63.71
$63.71
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 2.07 | -2.434 |
| Jun '18 | 29.91 | -1.627 | |
| Mar '18 | 21.90 | -1.420 | |
| FY 2017 | Dec '17 | 37.92 | -1.479 |
| Sep '17 | 17.10 | -1.339 | |
| Jun '17 | 15.93 | -1.344 | |
| Mar '17 | 18.96 | -1.247 | |
| FY 2016 | Dec '16 | 17.45 | -1.316 |
| Sep '16 | 13.65 | -1.214 | |
| Jun '16 | 8.71 | -1.054 | |
| Mar '16 | 7.34 | -1.208 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 12 | 14.86 | 56.82 | 5.28 | 111.98 |
| Quarter Ending Mar-19 | 8 | 23.62 | 54.98 | 9.10 | 110.26 |
| Year Ending Dec-18 | 16 | 68.88 | 110.69 | 59.00 | 141.96 |
| Year Ending Dec-19 | 16 | 162.31 | 421.96 | 82.00 | 448.38 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 12 | -2.30 | -1.99 | -2.70 | -1.41 |
| Quarter Ending Mar-19 | 8 | -2.19 | -1.84 | -2.41 | -1.11 |
| Year Ending Dec-18 | 14 | -7.73 | -7.09 | -8.27 | -5.47 |
| Year Ending Dec-19 | 15 | -8.07 | -6.28 | -9.96 | -2.87 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 92.25 | 33.63 | |
| P/E High - Last 5 Yrs. | -- | 323.36 | 45.43 | |
| P/E Low - Last 5 Yrs. | -- | 90.29 | 24.43 | |
| Beta | 2.97 | 0.91 | 0.90 | |
| Price to Sales (TTM) | 170.48 | 116.41 | 5.77 | |
| Price to Book (MRQ) | 10.02 | 15.60 | 5.12 | |
| Price to Tangible Book (MRQ) | 10.02 | 14.89 | 6.54 | |
| Price to Cash Flow (TTM) | -- | 72.75 | 23.57 | |
| % Owned Institutions | 96.38 | 12.59 | 1.83 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.39 | 1.49 | |
| Dividend Yield - 5 Year Avg | -- | 0.31 | 1.50 | |
| Dividend 5 Year Growth Rate | -- | 2.65 | 5.08 | |
| Payout Ratio(TTM) | -- | 23.68 | 43.75 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 82.94 | 358.89 | 7.43 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 120.51 | 90.38 | 5.80 | |
| Sales - 5 Yr. Growth Rate | -10.64 | 31.32 | 10.19 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -27.58 | 36.71 | 21.03 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -20.86 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 39.68 | 10.79 | |
| Capital Spending - 5 Yr. Growth Rate | 118.68 | 39.59 | 15.12 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.98 | 2.28 |
| Current Ratio (MRQ) | 8.84 | 5.42 | 3.11 |
| LT Debt to Equity (MRQ) | 13.36 | 33.58 | 11.47 |
| Total Debt to Equity (MRQ) | 13.36 | 35.41 | 15.63 |
| Interest Coverage (TTM) | -- | -152.89 | 31.38 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 41.87 | 54.21 | |
| Gross Margin - 5 Yr. Avg. | -- | 49.14 | 51.98 | |
| EBITD Margin (TTM) | -661.41 | -- | -- | |
| EBITD - 5 Yr. Avg | -480.35 | -506.71 | 11.83 | |
| Operating Margin (TTM) | -680.48 | -728.63 | 4.90 | |
| Operating Margin - 5 Yr. Avg. | -533.41 | -526.19 | 7.44 | |
| Pre-Tax Margin (TTM) | -670.81 | -694.90 | 5.91 | |
| Pre-Tax Margin - 5 Yr. Avg. | -518.10 | -531.06 | 7.89 | |
| Net Profit Margin (TTM) | -670.81 | -696.67 | 2.16 | |
| Net Profit Margin - 5 Yr. Avg. | -496.94 | -534.50 | 4.12 | |
| Effective Tax Rate (TTM) | -- | 25.12 | 23.36 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 20.63 | 24.15 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 128,399 | 25,687,363 | 898,926,015 | |
| Net Income/Employee (TTM) | -861,313 | 2,194,067 | 106,550,787 | |
| Receivable Turnover (TTM) | 5.30 | 18.46 | 5.94 | |
| Inventory Turnover (TTM) | -- | 2.61 | 3.62 | |
| Asset Turnover (TTM) | 0.05 | 0.43 | 0.97 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -31.44 | -1.11 | 11.50 | |
| Return on Assets - 5 Yr. Avg. | -31.82 | 2.88 | 12.67 | |
| Return on Investment (TTM) | -33.58 | 0.28 | 15.02 | |
| Return on Investment - 5 Yr. Avg. | -35.07 | 1.84 | 16.45 | |
| Return on Equity (TTM) | -39.86 | 0.94 | 16.60 | |
| Return on Equity - 5 Yr. Avg. | -40.19 | 2.30 | 17.56 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 14.75 | -0.01 | -10.64 |
| EPS (TTM) % | -38.73 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Alnylam Pharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 66.44 | 60.70 | 99 | 57 |
| 13 Week | 45.87 | 38.77 | 99 | 62 |
| 26 Week | 152.83 | 133.61 | 99 | 81 |
| 52 Week | 238.72 | 187.09 | 99 | 47 |
| YTD | 227.59 | 187.69 | 99 | 60 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- Eli Lilly makes bet on gene-silencing drug firm Dicerna
- UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln
- With Hemlibra, Roche seeks to break into tight hemophilia circle
- With Hemlibra, Roche seeks to break into tight hemophilia circle
Institutional Holders
| % Shares Owned: | 90.59% |
| # of Holders: | 458 |
| Total Shares Held: | 91,522,389 |
| 3 Mo. Net Change: | -1,167,047 |
| # New Positions: | 41 |
| # Closed Positions: | 44 |
| # Increased Positions: | 195 |
| # Reduced Positions: | 177 |
| # Net Buyers: | 18 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.